title: Clinical application of growth factors for collection of circulating hematopoietic progenitors in breast cancer patients treated with high-dose cyclophosphamide.
abstract: Seventy-seven (68 operable breast cancer with > 9 metastatic axillary nodes and 9 inflammatory breast cancer) entered this study. During hematopoietic recovery after cancer therapy with high-dose cyclophosphamide (7 g/m2; HD-CTX) circulating hematopoietic progenitors were collected by leukapheresis (LK) in all patients and then cryopreserved for autologous transplantation. Following HD-CTX, 70 patients were treated with hematopoietic growth factor(s) for 14 days: 38 with rhGM-CSF (group a), 16 with rhIL-3 (group b), 11 with sequential rhIL-3 and rhGM-CSF (group c), 5 with sequential rhIL-3 and rhG-CSF (group d). Seven control patients (group e) did not receive any growth factor. Leukaphereses, carried out over 2-4 consecutive days per patient, were started earlier in group c and in group d patients (mean day: +12 after HD-CTX). The sequential administration of rhIL-3 and rhG-CSF (group d) resulted in clearly higher yield of CFU-GM and CD34+ cells per leukapheresis (65.9 x 10(4)/Kg versus 20.9 x 10(6)/Kg, respectively) if compared with other groups of treatment.
authors.affiliation: Division of Immunohematology, National Tumor Institute, Milano, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Ravagnani
authors.forename: P
authors.initials: P
authors.lastname: Notti
authors.forename: S
authors.initials: S
authors.lastname: Siena
authors.forename: M
authors.initials: M
authors.lastname: Bregni
authors.forename: L
authors.initials: L
authors.lastname: Zorzino
authors.forename: M
authors.initials: M
authors.lastname: Di Nicola
authors.forename: N
authors.initials: N
authors.lastname: Belli
authors.forename: A M
authors.initials: AM
authors.lastname: Gianni
authors.forename: G
authors.initials: G
authors.lastname: Pellegris
mesh_terms: D000328:Adult; D001943:Breast Neoplasms / Q000188:drug therapy / Q000628:therapy*; D015925:Cryopreservation; D003520:Cyclophosphamide / Q000008:administration & dosage*; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage; D016298:Hematopoietic Cell Growth Factors / Q000008:administration & dosage*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007377:Interleukin-3 / Q000008:administration & dosage; D007937:Leukapheresis; D008875:Middle Aged; D014182:Transplantation, Autologous
chemical_list: D016298:Hematopoietic Cell Growth Factors; D007377:Interleukin-3; D016179:Granulocyte Colony-Stimulating Factor; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D003520:Cyclophosphamide